Gad Getz

TL;DR: Observations suggest numerous therapeutic opportunities, including kinase inhibitors and antibody therapies for genes in the canonical signaling pathways, histone deacetylase inhibitor and novel molecules for chromatin gene mutations, and immune therapies, which should be targeted to specific patients based on genomic profiling of their cancers.

TL;DR: This study developed a robust statistic (NetSig) that integrates protein interaction networks with data from 4,742 tumor exomes and found that NetSig candidates induce tumors at rates that are comparable to those of known oncogenes and are ten-fold higher than those of random genes.

TL;DR: The findings suggest that cyclinE1/CDK2 is an important therapeutic target in HGSC, but that resistance to CDK 2 inhibitors may emerge due to upregulation of CDK2 target protein and through preexisting cellular polyploidy.

TL;DR: Tracking large numbers of individualized tumor mutations in cfDNA can improve MRD detection, but its sensitivity is driven by the number of tumor mutations available to track.